Posts

Vol.9 No.4-4: MiRNA-122 association with TNF-α in some liver diseases of Egyptian patients

/0 Comments/in , , /by

By: Ahmed Abdelhalim Yameny1, Sabah Farouk Alabd1, and Magda Ahmed M. Mansor2

1Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of      Sadat City, Egypt

2Department of Histology, Faculty of Medicine, Menoufia University, Egypt

Abstract:

Background:  Due to the high frequency of HCC, ongoing research is needed to find precise, non-invasive biomarkers for early identification and follow-up that will improve prognostic results. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: Serum miR-122 and TNF-α levels were increased in HCV and HBV infection significantly with p-value >0.001*compared to the control group, and their levels decreased when developed into HCC but still higher than the healthy subjects significantly with p-value >0.001. For discriminating HCV from HCV+HCC the cut-off for miR-122 was >7.1 at sensitivity 100%, specificity 100%, and the AUC was 1.0 (Excellent) P-value <0.001, also the sensitivity and specificity for TNF-α 72%, and 60% respectively with cut off >12.1 and AUC of 0.745 (Good) p-value 0.003. For discriminating HBV from HBV+HCC the cut-off for miR-122 was ≤6.4 at a sensitivity of 86.67% and specificity of 96%, and the AUC of miR-122 was 0.99 (Excellent) P-value <0.001, also the sensitivity and specificity for TNF-α 93.33%, and 48.0% respectively with cut-off ≤15.73, TNF-α has AUC of 0.527 (fair) it was not significant p-value 0.780.

MiRNA-122-association-with-TNF-α-in-some-liver-diseases-of-Egyptian-patients

Download PDF

Vol.3 No.4 – 2: miRNA-122 from Laboratory biomarker to the treatment of HCV

/0 Comments/in , , /by

By : Ahmed Abdelhalim Yameny

Abstract

     Hepatitis C virus (HCV) is an important human pathogen that infects as many as 185 million persons worldwide, In the long-term, this can lead to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma HCC, there is currently no vaccine for hepatitis C. About 15–45% of infected persons spontaneously clear the virus within 6 months of infection without any treatment, miRNAs are endogenous short single-stranded noncoding RNAs and they are post-transcriptional negative regulators of gene expression, about18-22 nucleotides long, and play a crucial role in the regulation of gene expression. Now there are over 2500  mature potential human microRNAs recorded in miRBase (version 20, accessed January 2014), 84 miRNAs in serum and plasma of HCV-infected patients to identify miRNAs that correlated with different stages histologically assessed liver disease severity and during HCV infection, miRNA-122 is the most abundant in the liver,miRNA-122 is responsible, for liver homeostasis, several studies showed that miRNA-122 is required for HCV replication in infected cells, it can use as a serum biomarker over alanine leucine transaminase(ALT) in predicting the presence of chronic HCV infection, miR-122 also plays a crucial role in the regulation of cholesterol and fatty acid metabolism in the adult liver, and was identified as a regulator for systematic iron homeostasis, therapies that target it could present an effective approach for the development of new HCV antiviral drugs, Recently, the development of the anti-miR122 therapeutic miravirsen. Miravirsen (formerly SPC3649) is a 15-base oligonucleotide that is complementary to part of miR-122 and is the first miRNA-targeting agent administered to patients. Miravirsen has demonstrated in vitro antiviral activity against all HCV genotypes, Miravirsen interferes with the functions of miR-122 both in viral proliferation and in cholesterol homeostasis, miravirsen has demonstrated broad antiviral activity and a relatively high genetic barrier to resistance.

miRNA-122-from-Laboratory-diagnosis-to-treatment-of-HCV-converted

Download PDF

Vol3 No.1 -2 : Hepatitis Delta Virus among Hepatitis B Virus Infected Patients in Jordan: Where Do We Stand?

/0 Comments/in , , /by

By : ’Samer F. Swedan, 2Ziad A. Elnasser and ’Majd N. Brik Hnidi

Abstract

Infection by Hepatitis Delta Virus (HDV) which can only replicate in the presence of Hepatitis B Virus (HBV) is a cause of significant morbidity and mortality worldwide. Prevalence of HDV in Jordan is lacking. Blood samples were randomly obtained from 100 patients seropositive for active HBV. Sera were analyzed using highly sensitive and specific ELISA kits for the presence of specific HBV and HDV antigens and antibodies. Overall, samples were collected from 70 males and 30 females with an average age of 37.9 years and an age range of 13-62 years. The 94% of samples were from individuals older than 18 years. All samples were confirmed for the presence of active HBV infection. The 1 and 3% of the HBV infected individuals demonstrated markers of active and recovered HDV infection, respectively. These findings suggest that HBV positive individuals have a small but significant risk of acquiring HDV. We recommend the implementation of periodical testing for HDV infection among all HBV infected individuals and the administration of the HBV vaccine to unvaccinated individuals.

بحث مجد
Download Issue